News

Belite Bio Inc. (BLTE) has entered the second quarter of 2026 with a pivotal milestone: the initiation of a rolling New Drug Application (NDA) for tinlarebant, its lead oral therapy for Stargardt disease type 1 (STGD1). The rolling submission is slated for completion in Q2 2026, following the company’s Phase 3 DRAGON trial, which provided the prima...

Full article

Barry Callebaut AG’s interim results triggered an 18 % decline in the stock to CHF1,085, despite revenues and statutory earnings per share aligning with analyst estimates. Analysts responded by downgrading their consensus forecasts: the 2026 revenue outlook is now CHF13.0 billion, an 8.8 % drop from the previous year, and statutory EPS is projected...

Full article

In addition to DCF analysis, we also examine Soitec's Price‑to‑Sales (P/S) ratio, which is close to the wider Semiconductor industry average of 4.43x but below the peer group average of 6.59x. Our Fair Ratio for Soitec is 3.90x, suggesting that the company is trading at a higher multiple than implied by its earnings growth profile and industry comp...

Full article

Using a Discounted Cash Flow (DCF) analysis, we estimate Soitec's intrinsic value to be €16.15 per share, implying an overvaluation of 505.8% compared to its current price. Our model assumes cash flows will improve from a loss of €69.8 million in the latest twelve months to €25.4 million in 2026 and €58.2 million by 2029.

Full article

Soitec's stock price has surged 53.5% over 7 days and 293.3% year-to-date, raising concerns about its valuation. Our valuation model gives Soitec a score of 1 out of 6, indicating that the current share price of €97.82 may be overly optimistic. The company's recent growth has been fueled by increased interest in the semiconductor sector, but longer...

Full article

Market‑valuation metrics suggest an attractive opportunity. The share price of $118.92 reflects a 38.40% intrinsic discount and a 10.20% gap to the current analyst target of $133.91. Autoliv’s current market cap sits close to its 52‑week high, reinforcing its standing as a leading provider of automotive safety systems amid rising vehicle‑safety man...

Full article

However, several risks were noted. SG&A costs have risen partly because of negative currency‑translation effects and higher personnel expenses. Raw‑material volatility has exposed the firm to a full‑year headwind estimated at $90 million, with a particular concern about supply‑chain constraints and price increases linked to geopolitical tensions in...

Full article

Operationally, gross profit increased by roughly $50 million and the gross margin widened by almost 60 basis points. CAPEX fell $9 million, a 3% decline from sales. The company’s return on capital employed was 23% and return on equity 24%, underscoring efficient use of invested capital. Efficiency initiatives, including direct‑labor productivity ga...

Full article

Autoliv reiterated its 2026 guidance, forecasting flat organic net‑sales growth, an adjusted operating margin of 10.5% to 11%, and operating cash flow of about $1.2 billion. Management cited strong performance in Asia—China, India, South Korea—as the backbone of the growth story and highlighted new motorcycle and wearable‑airbag product launches as...

Full article

Autoliv (NYSE:ALV) reported first‑quarter 2026 results that beat expectations across most metrics. Net sales rose 6.8% YoY to $2.75 billion, and non‑GAAP earnings per share climbed 11.4% to $2.05. Adjusted operating income was $245 million, with a margin of 8.9%. Operating cash flow, however, was negative $76 million due to temporary working‑capita...

Full article